Agendia Raises $65M in Private Financing | GenomeWeb

NEW YORK (GenomeWeb News) – Agendia said today it has raised $65 million in a private round of equity financing.

The funds will be used to further expand the company's Symphony suite of breast cancer tests and the continued development of "our personalized medicine pipeline," Agendia CEO David Macdonald said in a statement. The company recently launched its Symphony suite in a formalin-fixed, paraffin-embedded format, and will soon launch its ColoPrint recurrence test for stage II colon cancer prognosis and prediction, he added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.